# Ambroxol to Slow Progression in Parkinson Disease

> **NCT05778617** · PHASE3 · RECRUITING · sponsor: **University College, London** · enrollment: 330 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Ambroxol Hydrochloride (420mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05778617
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2029-02
- **Final completion:** 2029-09
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05778617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05778617, "Ambroxol to Slow Progression in Parkinson Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05778617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*